Market Place
Sourcing Support
Krazati fails CRC trial; approval at risk
30 Apr 2026 //
ENDPOINTS
BMS makes Beeline, bringing 5 assets to bio’s $300M Debut
16 Apr 2026 //
BIOSPACE
Boehringer Evaluates DLL3, PD-L1/VEGF-A Combo in SCLC
09 Apr 2026 //
GLOBENEWSWIRE
BMS Camzyos Shows Ph3 Efficacy In Adolescent oHCM Trial
29 Mar 2026 //
BUSINESSWIRE
Takeda Clears Path To FDA With Phase 3 Data On $4B Psoriasis Bet
28 Mar 2026 //
FIERCE BIOTECH
FDA approves Bristol Myers`s cancer drug for Hodgkin`s lymphoma
20 Mar 2026 //
FDA
BMS` Celmod Drug Improves Myeloma PFS In Phase 3
09 Mar 2026 //
FIERCE BIOTECH
BMS` ADC Hits Primary Endpoints In Phase 3 Breast Cancer Trial
27 Feb 2026 //
FIERCE BIOTECH
SC Clears Zydus to Sell Cancer Drug; BMS Told to Map Patents
11 Feb 2026 //
ECONOMICTIMES
BMS Turns Focus To New Growth Drivers As Legacy Meds Decline
05 Feb 2026 //
FIERCE PHARMA
OXB Inks Multi-Year Supply Deal With Bristol Myers Squibb
04 Feb 2026 //
GLOBENEWSWIRE
BMS Lauds Breyanzi`s Shutout Against Cancer With Soccer Legend
04 Feb 2026 //
FIERCE PHARMA
Bristol Myers Halts Zydus` Biosimilar Cancer Drug Sales
29 Jan 2026 //
ECONOMICTIMES
BMS pens $850M tumor pact with T-cell engager biotech Janux
22 Jan 2026 //
FIERCE BIOTECH
NICE Recommends Opdivo for Resectable NSCLC Cancer
21 Jan 2026 //
PHARMIWEB
T1D Fund Appoints Teresa Foy, Ph.D. to Advance Therapies
21 Jan 2026 //
PR NEWSWIRE
Scotland Approves Dual Immunotherapy for MMRd/MSI-H mCRC Cancer
20 Jan 2026 //
PHARMIWEB
Scotland Approves Dual Immunotherapy for MMRd/MSI-H mCRC
20 Jan 2026 //
PHARMIWEB
Syngene Expands Research Collaboration With Bristol Myers Squibb
20 Jan 2026 //
ECONOMICTIMES
BMS Initiates Early-Stage Ventures Amid Pharma`s Late-Stage Rush
12 Jan 2026 //
BIOSPACE
Bristol Myers Squibb Reports Phase 3 SCOUT-HCM Trial Success
12 Jan 2026 //
PHARMIWEB
Biotech Showcase Facilitates Investor, Pharma, And Media Access
08 Jan 2026 //
PHARMIWEB
Bristol Myers Lines Up Many Launches For India With `AI` Speed
24 Dec 2025 //
ECONOMICTIMES
FDA Grants Priority Review for Opdivo Plus Chemo in Lymphoma
11 Dec 2025 //
PHARMIWEB
BMS & BioNtech Unveil Promising Early Results for TNBC therapy
11 Dec 2025 //
INDPHARMAPOST
BioNTech, Bristol Myers Squibb Unveil Positive Phase 2 Results
09 Dec 2025 //
GLOBENEWSWIRE
BMS Shares Targeted Lymphoma Therapy Data at ASH
08 Dec 2025 //
BUSINESSWIRE
Terray Reaches AI Drug Discovery Milestone With BMS
03 Dec 2025 //
BUSINESSWIRE
Bristol Myers Squibb Showcases Hematology Pipeline At ASH 2025
01 Dec 2025 //
BUSINESSWIRE
Bristol Myers Must Face $6.7 B Lawsuit Over Delayed Cancer Drug
01 Dec 2025 //
REUTERS
BMS Gets EU Nod To Expand Breyanzi Use In Mantle Cell Lymphoma
24 Nov 2025 //
BUSINESSWIRE
Evotec Secure BMS Milestone in Protein Degradation IND Acceptance
12 Nov 2025 //
PHARMIWEB
BMS Boosts Cancer Trials With Sarah Cannon`s Platform
12 Nov 2025 //
FIERCE BIOTECH
Dispatch Bio Inks Clinical Supply Deal With Bristol Myers Squibb
04 Nov 2025 //
BUSINESSWIRE
BMS Removes 2 Clinical Programs From Pipeline
30 Oct 2025 //
FIERCE BIOTECH
BMS, Cabaletta`s CAR T Therapy Shows Promise In Small Lupus Study
28 Oct 2025 //
BIOSPACE
BMS Shows Sotyktu Efficacy In Psoriatic Arthritis & Lupus
27 Oct 2025 //
BUSINESS WIRE
Maplight Goes Public Via $250M IPO To Fund Cobenfy Competitor
27 Oct 2025 //
FIERCE BIOTECH
BMS Ph1 Breakfree-1 Data Show Promise for CD19 NEXT CAR T Therapy
25 Oct 2025 //
BUSINESSWIRE
Replimune`s Stock Spikes 100% On FDA Acceptance Of Resubmission
20 Oct 2025 //
FIERCE BIOTECH
Systimmune, Bristol Myers Squibb Unveil Global Phase I Results
17 Oct 2025 //
PR NEWSWIRE
Deck Bio And ReTrax Therapeutics Win 2025 BMS Golden Tickets
15 Oct 2025 //
PR NEWSWIRE
Ono`s BMS-Partnered IO Drug Passes Phase 2 Gastric Cancer Test
11 Oct 2025 //
FIERCE BIOTECH
BMS Inks $1.5B Deal To Pull Orbital Into Its Sphere Of Influence
10 Oct 2025 //
PRESS RELEASE
Maplight Illuminates $262M IPO Plans To Fund Cobenfy Competitor
07 Oct 2025 //
FIERCE BIOTECH
BMS`s Anti-MTBR-Tau Receives Fast Track designation For Alzheimer
05 Oct 2025 //
INDPHARMAPOST
Bristol Myers`s BMS-986446 Receives FDA Fast Track Designation
01 Oct 2025 //
BUSINESSWIRE
Bristol Myers Squibb Secures FDA Fast Track For BMS-986446
01 Oct 2025 //
BUSINESSWIRE
Bms, Takeda Join Peers In Push To Improve AI By Pooling Data
01 Oct 2025 //
FIERCE BIOTECH
Systimmune To Showcase Data On Izalontamab Brengitecan & BL-M07D1
24 Sep 2025 //
PR NEWSWIRE
BMS Midtrial Endpoint Addition Secures Phase 3 Win in Myeloma
24 Sep 2025 //
FIERCE BIOTECH
J&J`s IL-23 Drug Defeats Sotyktu in Phase 3 Psoriasis Trial
17 Sep 2025 //
PR NEWSWIRE
BioNTech, BMS Tout First Global Data for Pd-L1x Vegf Bispecific
09 Sep 2025 //
PRESS RELEASE
Braveheart Pays $65 M to Challenge BMS for Heart Disease Market
05 Sep 2025 //
FIERCE BIOTECH
U.S. FDA grants Breakthrough Therapy for Izalontamab Brengitecan
18 Aug 2025 //
PR NEWSWIRE
BMS’ Breyanzi Accepted for Review in Marginal Zone Lymphoma
04 Aug 2025 //
BUSINESSWIRE
BMS` Cobenfy Future Uncertain After Phase III Failure
31 Jul 2025 //
BIOSPACE
BMS`s sNDA for Sotyktu in Psoriatic Arthritis Under Review
21 Jul 2025 //
BUSINESSWIRE
BioNTech`s Chief Strategy Officer Heads for The Exit
17 Jul 2025 //
FIERCE BIOTECH
Biokin, having landed BMS deal, posts ph. 3 Bispecific ADC win
03 Jul 2025 //
FIERCE BIOTECH
